Using Interferon‐α2 & Ruxolitinib Combination Therapy to Treat Myeloproliferative Neoplasms
Interferon‐α2 and ruxolitinib combination therapy shows promise in treating myeloproliferative neoplasms, according to recent preliminary findings.
Myeloproliferative Neoplasms Impair Patient Employment Status & Work Productivity
Investigators have found
that the higher the symptom burden, the greater the detrimental impact on work productivity and daily activity for patients with myeloproliferative neoplasms.
Gene Found to Enable Deadly Myelodysplastic Syndromes
Investigators in Cincinnati have linked a gene with myelodysplastic syndromes, potentially offering the first step toward a new genetic therapy.
Understanding Genetics to Develop Future Treatments for Rare Cancers
Pauline Funchain MD, explains how better understanding of genetics can help shape future treatments for rare cancers.
Relatives of Patients with Myeloid Blood Cancer at Two-Fold Risk of Disease
Relatives of individuals with certain types of blood cancer may harbor inherited genetic changes that could influence their risk of developing diseases that arise from myeloid cells.
Cancer & Sickle Cell Disease Treatments Can Increase Risk of Infertility
Investigators find boys treated with alkylating agents or with hydroxyurea for sickle cell disease resulted in a significant reduction in spermatogonial cell counts, suggesting that these agents can affect fertility.
MDS/MPN Overlap Syndromes and Myelofibrosis
Dr. Eric Padrone, a hematologist from H. Lee Moffit Cancer Center, discusses current thinking on MDS/MPN overlap disorders and myelofibrosis.
CALR-Mutant Myeloproliferative Neoplasms Induced by MPL Downstream Activation
Study performed by researchers at Juntendo University reveals molecular mechanisms that trigger CALR-mutant
myeloproliferative neoplasms (MPNs).
Top 5 Rare Disease News of the Week—July 1, 2018
Stay up-to-date on the latest rare disease news by reading the top 5 articles of the week.
JAK Inhibitors to Treat Myelofibrosis Could Lead to Development of Lymphomas
Researchers find that JAK inhibitors used to treat myelofibrosis may actually lead to the development of aggressive lymphomas.
Next Page >>
STRATEGIC ALLIANCE PARTNERSHIP PROGRAM >
Familial Chylomicronemia Syndrome
MJH ASSOCIATES >
Specialty Pharmacy Times
Terms & Conditions
Copyright © RareDR 2013-2018 Rare Disease Communications. All Rights Reserved.